Skip to content

H.R. 3008 · 118th Congress (2023–2025)

Drug Shortage Prevention Act of 2023

This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage.

Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies.

The bill requires drug manufacturers to also notify the FDA if there is an increased demand for such drugs that lasts for at least six weeks and that may result in a shortage. Manufacturers must initially notify the FDA of the increased demand within 48 hours after this six-week period and must submit an additional notice within 30 days of the initial notification. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 3008’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Sara Jacobs (D-CA-51)
Cosponsors
49 cosponsors

29 original · 20 later

2 R · 47 D

  1. Rep. Colin Z. Allred (D-TX-32)· Original · Apr 28, 2023
  2. Rep. Lisa Blunt Rochester (D-DE)· Original · Apr 28, 2023
  3. Rep. Emanuel Cleaver (D-MO-5)· Original · Apr 28, 2023
  4. Rep. Yvette D. Clarke (D-NY-9)· Original · Apr 28, 2023
  5. Rep. Steve Cohen (D-TN-9)· Original · Apr 28, 2023
  6. Rep. Troy A. Carter (D-LA-2)· Original · Apr 28, 2023
  7. Rep. Jasmine Crockett (D-TX-30)· Original · Apr 28, 2023
  8. Rep. Yadira Caraveo (D-CO-8)· Original · Apr 28, 2023
  9. Rep. Lloyd Doggett (D-TX-37)· Original · Apr 28, 2023
  10. Rep. Raúl M. Grijalva (D-AZ-7)· Original · Apr 28, 2023
  11. Rep. Jesús G. "Chuy" García (D-IL-4)· Original · Apr 28, 2023
  12. Rep. Jared Huffman (D-CA-2)· Original · Apr 28, 2023
  13. Rep. Sheila Jackson Lee (D-TX-18)· Original · Apr 28, 2023
  14. Rep. Ann M. Kuster (D-NH-2)· Original · Apr 28, 2023
  15. Rep. Ro Khanna (D-CA-17)· Original · Apr 28, 2023
  16. Rep. Andy Kim (D-NJ-3)· Original · Apr 28, 2023
  17. Rep. Barbara Lee (D-CA-12)· Original · Apr 28, 2023
  18. Rep. John B. Larson (D-CT-1)· Original · Apr 28, 2023
  19. Rep. James P. McGovern (D-MA-2)· Original · Apr 28, 2023
  20. Rep. Cory Mills (R-FL-7)· Original · Apr 28, 2023
  21. Del. Eleanor Holmes Norton (D-DC)· Original · Apr 28, 2023
  22. Rep. Alexandria Ocasio-Cortez (D-NY-14)· Original · Apr 28, 2023
  23. Rep. Ayanna Pressley (D-MA-7)· Original · Apr 28, 2023
  24. Rep. Adam Smith (D-WA-9)· Original · Apr 28, 2023
  25. Rep. Adam B. Schiff (D-CA-28)· Original · Apr 28, 2023
  26. Rep. Jill N. Tokuda (D-HI-2)· Original · Apr 28, 2023
  27. Rep. Nydia M. Velázquez (D-NY-7)· Original · Apr 28, 2023
  28. Rep. Marc A. Veasey (D-TX-33)· Original · Apr 28, 2023
  29. Rep. Bonnie Watson Coleman (D-NJ-12)· Original · Apr 28, 2023
  30. Rep. Kathy Castor (D-FL-14)· Later · Jun 5, 2023
  31. Rep. Angie Craig (D-MN-2)· Later · Jun 6, 2023
  32. Rep. Elissa Slotkin (D-MI-7)· Later · Jun 12, 2023
  33. Rep. Stephanie I. Bice (R-OK-5)· Later · Jun 14, 2023
  34. Rep. John P. Sarbanes (D-MD-3)· Later · Jun 15, 2023
  35. Rep. Madeleine Dean (D-PA-4)· Later · Jun 20, 2023
  36. Rep. Patrick Ryan (D-NY-18)· Later · Jun 21, 2023
  37. Rep. Christopher R. Deluzio (D-PA-17)· Later · Jul 11, 2023
  38. Rep. Sharice Davids (D-KS-3)· Later · Jul 11, 2023
  39. Rep. Lizzie Fletcher (D-TX-7)· Later · Jul 11, 2023
  40. Rep. Tony Cárdenas (D-CA-29)· Later · Jul 17, 2023
  41. Rep. Scott H. Peters (D-CA-50)· Later · Jul 20, 2023
  42. Rep. Val T. Hoyle (D-OR-4)· Later · Jul 26, 2023
  43. Rep. Maxwell Frost (D-FL-10)· Later · Aug 29, 2023
  44. Rep. Teresa Leger Fernandez (D-NM-3)· Later · Nov 14, 2023
  45. Rep. Stephen F. Lynch (D-MA-8)· Later · Dec 5, 2023
  46. Rep. Mike Quigley (D-IL-5)· Later · Jun 4, 2024
  47. Rep. Chris Pappas (D-NH-1)· Later · Jul 5, 2024
  48. Rep. Rashida Tlaib (D-MI-12)· Later · Jul 10, 2024
  49. Rep. Paul Tonko (D-NY-20)· Later · Jul 18, 2024
Policy area
Health
Subjects
  • Emergency medical services and trauma care
  • Government information and archives
  • Manufacturing
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Apr 28, 2023 – May 5, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Apr 28, 2023
  2. HouseHealthReferred May 5, 2023
    1. Sep 14, 2023 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Drug Shortage Prevention Act of 2023

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes.

    Official title · Introduced in House